Significant Difference in p53 and p21 Protein Immunoreactivity in HPV 16 Positive and HPV Negative Breast Carcinomas

Author： Hennig Elin M.   Kvinnsland Stener   Holm Ruth   Nesland Jahn M.  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.38, Iss.7, 1999-11, pp. : 931-938

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HPV16 infection regulates RASSF1A transcription mediated by p53

By        

Molecular Medicine Reports, Vol. 8, Iss. 2, 2013-01 ,pp. : 413-418

Spandidos Publications

Access to resources Recommend Favorite

Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro

By                  

Oncology Reports, Vol. 27, Iss. 1, 2012-01 ,pp. : 270-280

Spandidos Publications

Access to resources Recommend Favorite

Roles of p53 and p16 in triple-negative breast cancer

By Dang Daniel   Peng Yan  

Breast Cancer Management, Vol. 2, Iss. 6, 2013-11 ,pp. : 537-544

Future Medicine

Access to resources Recommend Favorite

Correlation between p53 mutations and HPV in bilharzial bladder cancer

By Khaled H.M.   Bahnassi A.A.   Zekri A.-R.N.   Kassem H.A.   Mokhtar N.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 334-341

Elsevier

Access to resources Recommend Favorite

The carcinogenic role of oncogenic HPV and p53 gene mutation in cervical adenocarcinomas

By Andersson S.   Hellström A.   Ren Zhi-Ping   Wilander E.  

Medical Oncology, Vol. 23, Iss. 1, 2006-03 ,pp. : 113-119

Humana Press, Inc

Access to resources Recommend Favorite